Validating Well-Functioning Hepatic Organoids for Toxicity Evaluation

Area of Science:

• Biotechnology
• Drug Development
• Toxicology

Background:

• Organoids are 3D organ-like tissues bridging animal and human studies in drug development.
• Current organoid toxicity studies are limited, necessitating further research.
• Human hepatic organoids offer a potential in vitro model for drug-induced liver injury assessment.

Purpose of the Study:

• To analyze the functionality and gene expression of human hepatic organoids derived from induced pluripotent stem cells.
• To utilize these organoids for toxicity assessment of known hepatotoxic and non-hepatotoxic substances.
• To validate hepatic organoids as a reliable model for drug toxicity evaluation.

Main Methods:

• Induced pluripotent stem cell-derived hepatic organoids were differentiated and characterized.
• Functional assessments included glycogen storage, albumin/bile acid secretion, and cytochrome P450 (CYP) activity.
• Toxicity evaluations were performed using ketoconazole, troglitazone, tolcapone (hepatotoxic), and sucrose, ascorbic acid, biotin (non-hepatotoxic).

Main Results:

• Hepatic organoids demonstrated functional similarity to the human liver.
• The organoid model successfully differentiated between hepatotoxic and non-hepatotoxic substances.
• Toxicological changes in hepatotoxic drug-treated organoids were analyzed, confirming model efficacy.

Conclusions:

• Functionally validated human hepatic organoids are promising models for drug toxicity evaluation.
• These organoids can accurately assess drug-induced liver injury.
• Hepatic organoids offer a valuable tool for advancing preclinical drug safety testing.